Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 39

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 39
---
 — |   |          — |

| (1) | Mr. Mack served as our Chief Financial Officer from April 8, 2024 to January 7, 2025. From June 25, 2024 to January 7, 2025, Mr. Mack also served as our Interim Chief Executive Officer, a role for which he received no additional compensation. He was appointed as our permanent Chief Executive Officer effective January 6, 2025. The Compensation Committee determined, at its own discretion, that Mr. Mack had earned 30% of his target bonus for 2024 based on additional achievements and his overall performance, equal to a bonus of $150,000. |

| (2) | Mr. Fuggetta served as our Principal Financial Officer from February 21, 2024 to April 5, 2024. He was appointed as our Senior Vice President Finance and Principal Financial Officer effective January 6, 2025. The Compensation Committee determined, at its own discretion, that Mr. Fuggetta had earned a 10% discretionary bonus, equal to a bonus of ₣18,000. |

| (3) | Mr. Alder was appointed as our Chief Executive Officer effective September 20, 2022 and served as our Chief Executive Officer until June 25, 2024. |

| (4) | Mr. Ballantyne was appointed as our Chief Financial Officer effective April 10, 2023 and served as our Chief Financial Officer until March 1, 2024. |

In December 2024, the Compensation Committee completed an evaluation of our overall performance for 2024 and the named executive officers’ respective contributions in achieving this performance. The Compensation Committee’s review was based on company performance against corporate objectives previously approved by the Board. Following such review, the Compensation Committee determined that less than 60% of the corporate performance objectives were achieved. Therefore, the Compensation Committee determined, at its own discretion, that Mr. Mack had earned 30% of his target bonus for 2024 based on additional achievements and his overall performance, equal to a bonus of $150,000, and Mr. Fuggetta had earned a 10% discretionary bonus, equal to a bonus of ₣18,000. Since Mr. Alder was terminated before the Compensation Committee’s review, no performance bonus would be paid to Mr. Alder in connection with his services for the year ended December 31, 2024